Roche and Genentech’s latest AI collaborator raises $25M Series A to reinvent one of the oldest cancer targets, check this link for more detail:
The biotech will use machine learning and other computational methods to study the structure of kinases and ultimately design drugs that can knock them out. Kinases may seem an old and solved problem, but it was pointed out that they are also an area where specificity becomes crucial; a “healthy” kinase and an oncogenic one may only differ by an amino acid or two, and a drug that hits both may run into the kind of safety issues that plagued the Pi3K space for a decade. New tools can help discern the difference.
Looking forward to some breakthrough soon, Lei!